Toru Maruyama
Overview
Explore the profile of Toru Maruyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
401
Citations
4656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsuzaki H, Kai K, Komohara Y, Yano H, Pan C, Fujiwara Y, et al.
Cancer Sci
. 2025 Feb;
PMID: 39921277
Glioblastoma (GBM) involves disruptions in the blood-brain barrier (BBB) and alterations in the immune microenvironment, including the activation of glioma-associated macrophages (GAMs). Vascular endothelial growth factor inhibitors, commonly used in...
2.
Ezaki A, Yano H, Pan C, Fujiwara Y, Anami T, Ibe Y, et al.
Cancer Genomics Proteomics
. 2024 Dec;
22(1):103-111.
PMID: 39730181
Background/aim: α1-Acid glycoprotein (AGP), also known as orosomucoid, is an acute-phase protein that has been found increased in plasma of cancer patients. This study investigates the role of AGP expression...
3.
Tokumaru K, Imafuku T, Satoh T, Inazumi T, Hirashima S, Nishinoiri A, et al.
Kidney360
. 2024 Sep;
5(10):1422-1434.
PMID: 39259608
No abstract available.
4.
Yanagisawa H, Maeda H, Noguchi I, Tanaka M, Wada N, Nagasaki T, et al.
Redox Biol
. 2024 Aug;
76:103314.
PMID: 39163766
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of nonalcoholic fatty liver disease characterised by fat accumulation, inflammation, oxidative stress, fibrosis, and impaired liver regeneration. In this study, we found...
5.
Taguchi K, Hashimoto M, Tokuno M, Takeoka S, Maruyama T, Yamasaki K, et al.
Xenobiotica
. 2024 Aug;
54(9):624-628.
PMID: 39087517
In the process of the drug development, studies on the cytochrome P450 (CYP) profiles after its administration provided fundamental information regarding drug interactions with concomitantly administered drugs. Here, we evaluated...
6.
Nakamura Y, Watanabe H, Nakamura T, Chirifu M, Ishiodori K, Imafuku T, et al.
Mol Pharm
. 2024 Jul;
21(8):4038-4046.
PMID: 38949624
The plasma protein α-acid glycoprotein (AGP) primarily affects the pharmacokinetics of basic drugs. There are two AGP variants in humans, A and F1*S, exhibiting distinct drug-binding selectivity. Elucidation of the...
7.
Nakamura Y, Watanabe H, Imafuku T, Fujita I, Ganaha Y, Takeo T, et al.
Mol Pharm
. 2024 Jun;
21(7):3144-3150.
PMID: 38862418
α-Acid glycoprotein (AGP) is a primary binding protein for many basic drugs in plasma. The number of drugs that bind to AGP, such as molecular target anticancer drugs, has been...
8.
Iwamoto N, Kai T, Inuki S, Ohno H, Maeda H, Watanabe H, et al.
Bioconjug Chem
. 2024 May;
35(6):816-825.
PMID: 38781049
Human serum albumin (HSA) as a drug carrier can significantly improve the pharmacokinetic profiles of short-lived therapeutics. Conjugation of albumin-binding moieties (ABMs) to therapeutic agents may prolong their serum half-life...
9.
Maruyama T, Kondo S, Nomura H
Geriatr Gerontol Int
. 2024 May;
24(7):737-738.
PMID: 38757362
No abstract available.
10.
Noguchi I, Maeda H, Kobayashi K, Nagasaki T, Kato H, Yanagisawa H, et al.
Free Radic Biol Med
. 2024 Apr;
220:67-77.
PMID: 38657755
Sarcopenia is characterized by loss of muscle strength and muscle mass with aging. The growing number of sarcopenia patients as a result of the aging population has no viable treatment....